van Rossum Leo G M, van Rijn Anne F, van Oijen Martijn G H, Fockens Paul, Laheij Robert J F, Verbeek Andre L M, Jansen Jan B M J, Dekker Evelien
Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Int J Cancer. 2009 Aug 15;125(4):746-50. doi: 10.1002/ijc.24458.
Delayed return of immunochemical fecal occult blood test (iFOBT) samples to a laboratory might cause false negatives because of hemoglobin degradation. Quantitative iFOBT's became increasingly more accepted in colorectal cancer screening. Therefore, we studied the effects of delay between sampling and laboratory delivery on iFOBT performance. IFOBT positivity (>or=50 ng/ml hemoglobin) in colorectal cancer screening participants without delay between sampling and laboratory delivery (<5 days), was compared with positivity in participants with >or=5 and >or=7 days delay. Additionally, positive tests were stored at room temperature and retested 5 times within 10-14 days. The sampling date was reported by 61% (n = 3,767) of the participants: in 19% delay was >or=5 days and in 5% >or=7 days. Compared with no-delay, the adenoma detection rate was already significantly decreased after >or=5 days delay (OR 0.6; 95%CI 0.4-0.9). We retested iFOBT samples of 170 positives of which 139 (82%) had a colonoscopy: 45 (32%) had advanced adenomas (not colorectal cancer) and 8 (6%) had colorectal cancer. Mean daily fecal hemoglobin decrease was 29 ng/ml (S.D. 38 and median 11 ng/ml). In patients with advanced adenomas, hemoglobin in the sample was <50 ng/ml in 5 (11%) 2-3 days after the initial test and in 16 (36%) after 10-14 days. Seven days after the initial test, 2 (25%) colorectal cancer patients became false negative. Both had stage I colorectal cancer and initial values below 100 ng/ml, where the average for stage I is 532 ng/ml. Delay in sample return increased false negative immunochemical FOBT's. Mainly precursor lesions, but also colorectal cancer, will be missed due to delayed sample return.
免疫化学粪便潜血试验(iFOBT)样本延迟送回实验室可能会因血红蛋白降解而导致假阴性结果。定量iFOBT在结直肠癌筛查中越来越被广泛接受。因此,我们研究了采样与实验室送检之间的延迟对iFOBT检测性能的影响。将结直肠癌筛查参与者中采样与实验室送检之间无延迟(<5天)时的iFOBT阳性率(血红蛋白≥50 ng/ml)与延迟≥5天和≥7天的参与者的阳性率进行比较。此外,将阳性检测样本在室温下保存,并在10 - 14天内进行5次复测。61%(n = 3767)的参与者报告了采样日期:19%的参与者延迟≥5天,5%的参与者延迟≥7天。与无延迟相比,延迟≥5天后腺瘤检出率已显著降低(比值比0.6;95%置信区间0.4 - 0.9)。我们对170例阳性iFOBT样本进行了复测,其中139例(82%)进行了结肠镜检查:45例(32%)患有高级别腺瘤(非结直肠癌),8例(6%)患有结直肠癌。粪便血红蛋白平均每日下降29 ng/ml(标准差38,中位数11 ng/ml)。在患有高级别腺瘤的患者中,初次检测后2 - 3天,样本中的血红蛋白<50 ng/ml的有5例(11%),10 - 14天后有16例(36%)。初次检测7天后,2例(25%)结直肠癌患者出现假阴性。这两名患者均为I期结直肠癌,初始值低于100 ng/ml,而I期的平均值为532 ng/ml。样本送回延迟会增加免疫化学FOBT的假阴性结果。由于样本送回延迟,主要是前驱病变以及结直肠癌都可能会被漏诊。